BFM
RNTX

Boothbay Fund Management’s Rein Therapeutics RNTX Stock Holding History

Boothbay Fund Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,937
Closed -$72K – 2664
2022
Q2 		$72K Hold
13,937
– – ﹤0.01% 2038
2022
Q1 		$143K Hold
13,937
– – ﹤0.01% 2009
2021
Q4 		$157K Sell
13,937
-1,679
-11% -$26K ﹤0.01% 1574
2021
Q3 		$319K Sell
15,616
-4,035
-21% -$88.4K 0.01% 1302
2021
Q2 		$491K Buy
19,651
+2,070
+12% +$51.6K 0.02% 1013
2021
Q1 		$503K Buy
+17,581
New +$602K 0.02% 943

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boothbay Fund Management's RNTX Position: Q3 2022 in Review

Boothbay Fund Management sold out of Rein Therapeutics (RNTX) in Q3 2022, closing a stake of 13,937 shares — an estimated $72K sold.

Boothbay Fund Management first reported a position in RNTX in Q1 2021 and held it in 6 quarters. The position peaked at $503K in Q1 2021. 33 funds tracked by Wall St. Rank hold RNTX as of Q3 2022.

  • Boothbay Fund Management reported no remaining Rein Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 13,937 Rein Therapeutics shares in Q3 2022, an estimated $72K.
  • Boothbay Fund Management first reported a position in Rein Therapeutics in Q1 2021 and held it in 6 quarters.
  • Boothbay Fund Management's Rein Therapeutics position peaked at $503K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.